Novo Nordisk A/S (Novo Nordisk A/S) EV-to-Revenue

: 16.41 (As of Today)

View and export this data going back to 1981. Start your Free Trial

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Novo Nordisk A/S's enterprise value is $551,677 Mil. Novo Nordisk A/S's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $33,619 Mil. Therefore, Novo Nordisk A/S's EV-to-Revenue for today is 16.41.

The historical rank and industry rank for Novo Nordisk A/S's EV-to-Revenue or its related term are showing as below:

NVO' s EV-to-Revenue Range Over the Past 10 Years
Min: 4.99 Med: 7.89 Max: 17.42
Current: 16.41

During the past 13 years, the highest EV-to-Revenue of Novo Nordisk A/S was 17.42. The lowest was 4.99. And the median was 7.89.

NVO's EV-to-Revenue is ranked worse than
64.69% of 1031 companies
in the Biotechnology industry
Industry Median: 7.58 vs NVO: 16.41

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-19), Novo Nordisk A/S's stock price is $123.755. Novo Nordisk A/S's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $7.48. Therefore, Novo Nordisk A/S's PS Ratio for today is 16.54.

Novo Nordisk A/S EV-to-Revenue Historical Data

The historical data trend for Novo Nordisk A/S's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

7.51

7.88

12.12

11.94

13.39

Novo Nordisk A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue																11.94	12.96	12.19	13.33	13.39

Competitive Comparison

For the Biotechnology subindustry, Novo Nordisk A/S's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novo Nordisk A/S EV-to-Revenue Distribution

For the Biotechnology industry and Healthcare sector, Novo Nordisk A/S's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Novo Nordisk A/S's EV-to-Revenue falls into.

Novo Nordisk A/S EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Novo Nordisk A/S's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	551676.986	/	33619.351
	=	16.41

Novo Nordisk A/S's current Enterprise Value is $551,677 Mil.
Novo Nordisk A/S's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $33,619 Mil.

Novo Nordisk A/S (NYSE:NVO) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Novo Nordisk A/S's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	123.755	/	7.482
	=	16.54

Novo Nordisk A/S's share price for today is $123.755.
Novo Nordisk A/S's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.48.

Novo Nordisk A/S EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (NYSE:NVO) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

NONOF:USA NOVOB:Mexico NVO:Mexico NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NOV:Germany NOVA:Germany NOV:Germany NOV:Germany NOVA:Germany N1VO34:Brazil NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, DK-2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.